

8 August 2019

ASX ANNOUNCEMENT

NOTICE TO TERMINATE DISTRIBUTION AGREEMENT

Admedus Limited (ASX:AHZ) (**Admedus** or the **Company**) has received notice from arcomed ag (**arcomed**) of its intention to terminate the distribution agreement with Admedus for the supply of arcomed branded products in Australia and New Zealand.

The Company has previously announced a strategic vision to focus on its' structural heart initiatives and as such the Company's recent efforts have been to complete transactions that deliver better outcomes for the customers of the Company's Infusion business and their patients. The Company will work with affected customers over the coming months to ensure that there is no impact to patient care.

The Company will provide a further update once the transitional terms have been agreed with arcomed and customers.

About Admedus Limited

Admedus (ASX:AHZ) is a structural heart company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing, profitable medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.

For more information:

Admedus@we-buchan.com

Website: www.admedus.com

Twitter: @Admedus

Facebook: www.facebook.com/pages/Admedus

Admedus Limited

Registered Office:

Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland 4066

Customer Service:

T: 1300 550 310 F: 1300 880 398 International: T: +61 (0)7 3152 3200 F: +61 (0)7 3152 3299

E: info@admedus.com W: admedus.com

